TROPHAMET, a phase I/II trial of Avelumab and METhotrexate in low-risk gestational TROPHoblastic neoplasias as first line treatment

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515434-32-00

Acronym

69HCL18 0857

Enrollment

Registered

2024-08-06

Start date

2020-02-12

Completion date

Unknown

Last updated

2025-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low-risk gestational trophoblastic neoplasia

None listed

Sex/Gender

All

Age

18 Years to 64 Years

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026